Evaluation of timolol in chronic open-angle glaucoma. Once a day vs twice a day
D. B. Soll
Regimens of once-a-day or twice-a-day 0.25% timolol ophthalmic solution
were compared for efficacy and tolerability in a four-week study of 41
patients with chronic open-angle glaucoma and elevated, untreated
intraocular pressure. Significant reductions in IOP relative to untreated
baseline values were achieved within a range of 18% to 25%. No significant
between-group differences were noted, although the twice-a-day group had
somewhat lower IOPs at each evaluation point and the once-a-day group had
somewhat fewer subjective symptoms of local irritation. A statistically
significant decrease from baseline in mean pulse rate was noted in the
twice-a-day treatment group after two weeks; no clinically significant or
serious adverse reactions occurred in any patient. Both once-daily and
twice-daily administrations of 0.25% timolol ophthalmic solution were found
to be effective and well tolerated in the population studied.
